Professor Justin Stebbing is Editor-in-Chief of Nature’s cancer journal Oncogene, a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at ARU, Cambridge. In October 2022 he joined the Phoenix Hospital Group in London to provide medical services to patients for the management of cancer, in person and remotely. He specialises in a range of solid malignancies (breast, GI, lung, others) including difficult cases with few conventional options and has published over 700 papers, the majority regarding new therapeutic and translational approaches including use of immunotherapies in clinical trials, many in the world's best journals.
Attributes | Values |
---|
rdfs:label
| |
rdfs:comment
| - Professor Justin Stebbing is Editor-in-Chief of Nature’s cancer journal Oncogene, a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at ARU, Cambridge. In October 2022 he joined the Phoenix Hospital Group in London to provide medical services to patients for the management of cancer, in person and remotely. He specialises in a range of solid malignancies (breast, GI, lung, others) including difficult cases with few conventional options and has published over 700 papers, the majority regarding new therapeutic and translational approaches including use of immunotherapies in clinical trials, many in the world's best journals. (en)
|
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
has abstract
| - Professor Justin Stebbing is Editor-in-Chief of Nature’s cancer journal Oncogene, a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at ARU, Cambridge. In October 2022 he joined the Phoenix Hospital Group in London to provide medical services to patients for the management of cancer, in person and remotely. He specialises in a range of solid malignancies (breast, GI, lung, others) including difficult cases with few conventional options and has published over 700 papers, the majority regarding new therapeutic and translational approaches including use of immunotherapies in clinical trials, many in the world's best journals. (en)
|
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is editor
of | |
is editor
of | |
is foaf:primaryTopic
of | |